Gilead to Acquire Maryland's Arcellx in $7.8B Deal
What happened
Gilead Sciences will acquire Maryland-based Arcellx for $7.8 billion, a major investment in the region's cell and gene therapy sector. The deal centers on Arcellx's CAR-T cell therapy for multiple myeloma, positioning Maryland as a strategic hub for cancer treatment innovation. This acquisition is part of a broader trend of significant investments in the life sciences industry.
Why it matters
- This deal builds upon a prior collaboration started in December 2022 between Arcellx and Gilead's cell therapy subsidiary, Kite. Gilead already owned 11.5% of Arcellx's stock before moving to acquire the remaining shares. - The acquisition price of $115 per share represents a 79% premium over Arcellx's closing stock price on the Friday before the announcement. Shareholders also have a potential future payout of $5 per share if the lead therapy, anito-cel, achieves $6 billion in cumulative sales by the end of 2029. - Gaithersburg-based Arcellx was founded in 2014 by David Hilbert and began its research in an 800-square-foot tech incubator space in 2015. The company went public on the Nasdaq in February 2022 at $15 per share. - The deal's central asset is anitocabtagene autoleucel (anito-cel), a CAR-T cell therapy for multiple myeloma. A decision on its approval from the U.S. Food and Drug Administration (FDA) is expected by December 23, 2026. - The acquisition gives Gilead full control over Arcellx's D-Domain technology platform, which could be used to develop next-generation cell therapies. This move eliminates the previous arrangement's profit-sharing, milestone payments, and royalties. - The global market for multiple myeloma therapeutics was valued at more than $20 billion in 2023, with projections expecting it to grow to nearly $38.4 billion by 2029. The overall CAR-T therapy market is also expanding rapidly, with some analysts forecasting it to exceed $22 billion by 2033. - This acquisition is one of Gilead's largest in the oncology space, following its transformative $11.9 billion purchase of Kite Pharma in 2017, which first established its presence in the cell therapy field.
Key numbers
- Gilead Sciences will acquire Maryland-based Arcellx for $7.8 billion, a major investment in the region's cell and gene therapy sector.
- - This deal builds upon a prior collaboration started in December 2022 between Arcellx and Gilead's cell therapy subsidiary, Kite.
- Gilead already owned 11.5% of Arcellx's stock before moving to acquire the remaining shares.
- The acquisition price of $115 per share represents a 79% premium over Arcellx's closing stock price on the Friday before the announcement.
What happens next
- Food and Drug Administration (FDA) is expected by December 23, 2026.
- The acquisition gives Gilead full control over Arcellx's D-Domain technology platform, which could be used to develop next-generation cell therapies.
- Gilead Sciences will acquire Maryland-based Arcellx for $7.8 billion, a major investment in the region's cell and gene therapy sector.
Quick answers
What happened in Gilead to Acquire Maryland's Arcellx in $7.8B Deal?
Gilead Sciences will acquire Maryland-based Arcellx for $7.8 billion, a major investment in the region's cell and gene therapy sector. The deal centers on Arcellx's CAR-T cell therapy for multiple myeloma, positioning Maryland as a strategic hub for cancer treatment innovation. This acquisition is part of a broader trend of significant investments in the life sciences industry.
Why does Gilead to Acquire Maryland's Arcellx in $7.8B Deal matter?
This deal builds upon a prior collaboration started in December 2022 between Arcellx and Gilead's cell therapy subsidiary, Kite. Gilead already owned 11.5% of Arcellx's stock before moving to acquire the remaining shares. The acquisition price of $115 per share represents a 79% premium over Arcellx's closing stock price on the Friday before the announcement. Shareholders also have a potential future payout of $5 per share if the lead therapy, anito-cel, achieves $6 billion in cumulative sales by the end of 2029. Gaithersburg-based Arcellx was founded in 2014 by David Hilbert and began its research in an 800-square-foot tech incubator space in 2015. The company went public on the Nasdaq in February 2022 at $15 per share. The deal's central asset is anitocabtagene autoleucel (anito-cel), a CAR-T cell therapy for multiple myeloma. A decision on its approval from the U.S. Food and Drug Administration (FDA) is expected by December 23, 2026. The acquisition gives Gilead full control over Arcellx's D-Domain technology platform, which could be used to develop next-generation cell therapies. This move eliminates the previous arrangement's profit-sharing, milestone payments, and royalties. The global market for multiple myeloma therapeutics was valued at more than $20 billion in 2023, with projections expecting it to grow to nearly $38.4 billion by 2029. The overall CAR-T therapy market is also expanding rapidly, with some analysts forecasting it to exceed $22 billion by 2033. This acquisition is one of Gilead's largest in the oncology space, following its transformative $11.9 billion purchase of Kite Pharma in 2017, which first established its presence in the cell therapy field.
